Dr. Han Phan
Claim this profileRare Disease Research, LLC
Studies Duchenne Muscular Dystrophy
Studies Excessive Daytime Sleepiness
21 reported clinical trials
22 drugs studied
About Han Phan
Education:
- Received MD from Morehouse School of Medicine.
Experience:
- Pediatric neurologist and sleep specialist with extensive clinical experience.
- Founder of Rare Disease Research, LLC, focusing on enhancing clinical trial access for rare disease patients.
- Completed residency at the University of Alabama, specializing in pediatric neurology and sleep medicine.
Area of expertise
1Duchenne Muscular Dystrophy
dystrophin positive
DMD gene mutation positive
DMD negative
2Excessive Daytime Sleepiness
CTG repeat positive
Affiliated Hospitals
Clinical Trials Han Phan is currently running
Pitolisant
for Prader-Willi Syndrome
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (EDS) in patients ≥6 years of age with Prader-Willi syndrome. Secondary objectives include assessing the impact of pitolisant on: Irritable and disruptive behaviors Hyperphagia Other behavioral problems including social withdrawal, stereotypic behavior, hyperactivity/noncompliance, and inappropriate speech
Recruiting1 award Phase 3
Galcanezumab
for Migraine
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Recruiting1 award Phase 31 criteria
More about Han Phan
Clinical Trial Related2 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Han Phan has experience with
- Placebo
- Nusinersen
- Corticosteroids
- Pamrevlumab
- Galcanezumab
- SRP-5051
Breakdown of trials Han Phan has run
Duchenne Muscular Dystrophy
Excessive Daytime Sleepiness
Prader-Willi Syndrome
Spinal Muscular Atrophy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Han Phan specialize in?
Han Phan focuses on Duchenne Muscular Dystrophy and Excessive Daytime Sleepiness. In particular, much of their work with Duchenne Muscular Dystrophy has involved dystrophin positive patients, or patients who are DMD gene mutation positive.
Is Han Phan currently recruiting for clinical trials?
Yes, Han Phan is currently recruiting for 5 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Han Phan has studied deeply?
Yes, Han Phan has studied treatments such as Placebo, Nusinersen, Corticosteroids.
What is the best way to schedule an appointment with Han Phan?
Apply for one of the trials that Han Phan is conducting.
What is the office address of Han Phan?
The office of Han Phan is located at: Rare Disease Research, LLC, Atlanta, Georgia 30318 United States. This is the address for their practice at the Rare Disease Research, LLC.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.